This message was sent to ##Email##
|
|
|
|
|
| |
 REGISTER NOW!
Join us for SCAI 2019 Scientific Sessions in Las Vegas from Sunday, May 19, through Wednesday, May 22. Come and see a distinguished faculty present the latest research and developments in interventional cardiology through a mix of live cases, featured speakers, case reviews, lectures, interactive discussions, abstract presentations, poster sessions and more.
Register now to take advantage of the early bird rate.
Learn about appropriate screening and non-invasive testing for peripheral artery disease in Module 2 of SCAI’s PAD Diagnosis and Treatment Resource Center. Watch the video lecture by Larry Diaz, MD, FSCAI or download the PowerPoint, authored by Dr. Diaz and Mehdi Shishehbor, DO, FSCAI. This initiative is supported by an educational grant from Janssen.
Recognizing SCAI Members for Excellence in Invasive/Interventional Cardiology
Nominate a colleague for Master Interventionalist of SCAI (MSCAI) today!
MSCAI are elected for outstanding achievements in — and contributions to — the field of cardiac and/or endovascular angiography and/or intervention. An MSCAI is recognized for having demonstrated excellence over a career, manifested by a commitment to the highest levels of clinical care, innovation, research and, and/or teaching. SCAI needs your help to identify those invasive/interventional cardiologists who meet the requirements for this year's class.
The submission deadline is November 25, 2018.
Pulsara
In the cohort of patients, the utilization of the Pulsara platform decreased the average door-to-balloon times by 22% in patients with acute STEMI arriving at the emergency department. This effect was maintained when looking at the subset of all STEMI cases reportable to CMS. Researchers also observed modest improvements in meeting the less than 60-minute, less than 90-minute benchmarks, and improvements in the resource utilization. Read the full Critical Pathways in Cardiology publication here.
READ MORE
| | CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS |
MedPage Today
Hemodynamic deterioration of a transcatheter aortic valve replacement was more common with younger age, absence of dual antiplatelet therapy after the procedure and lower left ventricular ejection fraction at baseline. In the single-center experience, 3 percent of patients developed moderate-to-severe valve stenosis over 3.3 years' follow-up. (Catheterization and Cardiovascular Interventions)
READ MORE
TCTMD
Interventional cardiologists still have mixed perspectives on appropriate use criteria (AUC) for diagnostic catherization and percutaneous coronary interventions nearly a decade after the metrics debuted, according to results of a recent survey.
Only half of those who replied said the AUC process has been helpful to their patients and cath lab, a finding that the researchers describe as “disturbing” in their paper, published online in Catheterization and Cardiovascular Interventions.
READ MORE
|
|
|
|
|
| |
Cath Lab Digest
Abbott announced that the HeartMate 3™ Left Ventricular Assist Device has received U.S. Food and Drug Administration approval as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not eligible for a transplant who will live with their device for the rest of their lives.
READ MORE
MedPage Today
Frail older adults undergoing transcatheter aortic valve replacement (TAVR) may not tolerate nonfemoral access as well as do other peers, according to a post hoc analysis of the FRAILTY-AVR study.
These patients were more likely to die shortly after a more invasive nonfemoral TAVR at both 30 days and one year.
READ MORE
Cardiovascular Business
Despite past research suggesting a history of percutaneous coronary intervention (PCI) could complicate coronary artery bypass grafting outcomes, a study published in the Journal of the American Heart Association Oct. 16 reported prior PCI has little to do with how a patient recovers from subsequent surgeries.
“Multiple prior PCI procedures and multiple treated vessels could hypothetically be associated with worse outcome, but scarce data exist to substantiate this,” first author Fausto Biancari, MD, PhD, and co-authors wrote in JAHA.
READ MORE
For a complete list of job postings, click here.
To post your resume, click here.
| Date |
Event |
Location |
| Nov. 4-5,
2018 |
The VEINS at VIVA 2018 |
Las Vegas, NV
|
| Nov. 5-8, 2018 |
VIVA 18 |
Las Vegas, NV
|
| Dec. 2-4, 2018 |
Innovations in Cardiovascular Interventions Israel Meeting |
ICI, Israel
|
| Dec. 7-11, 2018 |
SCAI Fall Fellows 2018 Courses |
Las Vegas, NV
|
| Dec. 8-9, 2018 |
New York City Debates in Interventional Cardiology |
New York, NY
|
| Jan. 10-12, 2019 |
KSIC 2019 featuring SCAI Session on Fundamentals of Structural Heart Disease |
Seoul, South Korea
|
| Jan. 30-Feb. 1, 2019 |
CardioMilitary 2019 & SCAI Regional Mentor Course |
Cairo, Egypt
|
| May 19-22, 2019 |
SCAI 2019 Scientific Sessions |
Las Vegas, NV
|
| Sept. 14-15, 2019 |
SCAI i3 – Interface in Interventional Cardiology |
Mumbai, India
|
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
